The UK on Thursday approved two drugs to be used in treating patients with COVID-19, a disease caused by the CCP (Chinese Communist Party) virus, commonly known as novel coronavirus. The two new drugs, tocilizumab and sarilumab, typically used to treat rheumatoid arthritis, are monoclonal antibodies that target a protein called interleukin-6, which is thought to be important in the COVID-19 infection pathway. The drugs have shown effectiveness for patients requiring organ support, according to the Department of Health and Social Care (DHSC). Deputy Chief Medical Officer for England Jonathan Van-Tam said that data from a clinical trial showed that the drugs can speed up and improve the odds of recovery in intensive care. “Results from the government-funded REMAP-CAP clinical trial published today showed tocilizumab and sarilumab reduced the relative risk of death by 24%, when administered to patients within 24 hours of entering intensive care,” DHSC said in a statement. According to the DHSC, …